Holland Foundation for Sight Restoration launched to provide life-changing eye surgeries
This announcement was made at the 2021 ASCRS annual meeting.
COVID-19 has changed surgical preferences
A new report has found that glaucoma specialists’ procedure of choice has changed as a result of the COVID-19 pandemic.
CMS 2022 Physician Fee Schedule includes payment cut
AAO, Surgical Care Coalition teaming up to ensure the final version of the rule is fair to ophthalmologists and surgeons as one company is expressing its disappointment in the proposal.
First patient dosed in optogenetic gene therapy trial
Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.
OCT may have role in treatment of neurofibromatosis type 1
The Gilbert Family Foundation is collaborating with the Children’s Oncology Group and Children’s Hospital of Philadelphia to validate a tool to measure progressive vision loss.
FDA grants Investigational Device Exemption for MINIject in glaucoma patients
According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.
Breakthrough Therapy Designation granted by FDA for Alkeus Pharmaceuticals’ ALK-001 Stargardt disease treatment
Alkeus Pharmaceuticals, Inc, announced Thursday that the FDA has granted Breakthrough Therapy Designation (BTS) for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt disease.
Investigators study pathology of Usher syndrome
Usher syndrome 1G protein SANS regulates the splicing of genes, particularly those linked to Usher syndrome, which can lead to early vision loss form RP.
Belkin Laser changes corporate name to Belkin Vision
The company, formerly called BELKIN Laser, announced Thursday that it will begin operating under the new name BELKIN Vision.
Increase in black fungus infections offers new COVID-19 challenge
Physicians in India have reported 7,200 documented cases of mucormycosis infections in patients with severe COVID-19 infections.
ASCRS calls on Aetna to rescind new policy delaying cataract surgery
ASCRS has issued a statement calling on Aetna to drop a new prior authorization policy it implemented last week that delays cataract surgeries.
Maximizing CXL effectiveness
Ex vivo experiment identifies potential benefit for supplementary oxygen.
AMA unveils newly adopted trainee, resident policies
The American Medical Association recently announced policies adopted by physician and medical student leaders from all corners of medicine on the final day of the Special Meeting of the AMA House of Delegates.
Effect of mRNA vaccines against COVID-19 may have lasting impact
In an observational study, investigators are looking at the role of antibody secreting plasmablasts and GC B cells induced by the COVID-19 vaccines.
Predicting pandemics with early warning system
MedShr Insights has developed an early warning system that applies natural language processing, artificial intelligence, and machine learnings.
2020 On-site forms Industry and Scientific Advisory Board
The company’s IASAB will identify key business initiatives, ensuring they align with its strategic vision.
Pulling back the curtain on racial inequities in ocular health care
AAO develops task forces to evaluate academy, review outcomes in ophthalmology.
Santen earns FDA approval for cyclosporine ophthalmic emulsion eye drops to treat vernal keratoconjunctivitis
Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).
Genentech receives FDA acceptance of BLA for PDS with ranibizumab to treat wet AMD
If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.
Smartphone screening and referral increases access to care for people with eye problems
According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.
Artificial cornea implantation: High postop infectious keratitis rate
Postop management with long-term topical antibiotics is critical to successful device retention.
Oyster Point Pharma enrolls first subject in phase 2 clinical trial of OC-01 nasal spray for neurotrophic keratopathy
Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).
Biosensor for remote glaucoma care gets new approvals
Implandata received FDA Breakthrough Device Designation for its Eyemate-SC in April and now has CE Mark approval in the European Union.
AMA policy: Equitable distribution of resources needed to fight COVID-19
The American Medical Association is advocating equitable resource distribution of vaccinations to assist low-income countries.
Unlocking the keys to mild COVID-19 cases in infants
According to investigators, infants may have an edge over adults, with babies demonstrating a stronger immune response to the SARS-CoV-2 virus.
Touchless technology could enable early detection, treatment of eye diseases that cause blindness
According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.
Supreme Court upholds Affordable Care Act
The US Supreme Court ruled Thursday that the Affordable Care Act remains valid, rejecting a claim by several states that a recent change to the law made it unconstitutional.
ASCRS 2021 going live
The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.
AAO study: More than 96% of US ophthalmologists are vaccinated against COVID-19
The American Academy of Ophthalmology is calling on its members to continue to build confidence in COVID-19 vaccines and encourage people to get vaccinated, including their staff.
Clearside Biomedical reports positive safety results of cohort 1 trial of CLS-AX for nAMD
Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.
